Information Provided By:
Fly News Breaks for May 24, 2017
ALNY
May 24, 2017 | 13:43 EDT
Piper Jaffray analyst Edward Tenthoff views Alnylam Pharmaceuticals' 5M share offering as "smart" following the recent share rally and ahead of Phase III data on patisiran in September. The analyst looks for the company to launch multiple orphan drugs including patisiran in 2018, fitusiran in hemophilia in 2019 and givosiran in porphyria in 2020. He lowered his price target for the shares to $116 from $118 and reiterates an Overweight rating on Alnylam.
News For ALNY From the Last 2 Days
There are no results for your query ALNY